Who Exports Febuxostat from India — 182 Suppliers Behind a $48.9M Market
India's febuxostat export market is supplied by 182 active exporters who collectively shipped $48.9M across 3,494 shipments. AJANTA PHARMA LIMITED leads with a 34.4% market share, followed by MSN LABORATORIES PRIVATE LIMITED and ALEMBIC PHARMACEUTICALS LIMITED. The top 5 suppliers together control 73.0% of total export value, reflecting a concentrated market structure.
Top Febuxostat Exporters from India — Ranked by Export Value
AJANTA PHARMA LIMITED is the leading febuxostat exporter from India, holding a 34.4% share of the $48.9M market across 3,494 shipments from 182 exporters. The top 5 suppliers — AJANTA PHARMA LIMITED, MSN LABORATORIES PRIVATE LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, LUPIN LIMITED, MACLEODS PHARMACEUTICALS LTD — collectively control 73.0% of total export value, indicating a highly concentrated market. Individual shares are: AJANTA PHARMA LIMITED (34.4%), MSN LABORATORIES PRIVATE LIMITED (12.3%), ALEMBIC PHARMACEUTICALS LIMITED (11.0%), LUPIN LIMITED (10.9%), MACLEODS PHARMACEUTICALS LTD (4.4%).
Top Febuxostat Exporters from India
Ranked by export value · 182 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | AJANTA PHARMA LIMITED URINORM TAB 40MG FEBUXOSTAT TABLETS 40URINORM TAB 40MG (FEBUXOSTAT TABLETS 40FURIC 40 10X10T FEBUXOSTAT TABLETS 40MG | $16.8M | 6 | 34.4% |
| 2 | MSN LABORATORIES PRIVATE LIMITED URINORM TAB 40MG FEBUXOSTAT TABLETS 40URINORM TAB 40MG (FEBUXOSTAT TABLETS 40FEBUXOSTAT TABLETS 40MG 30 S AP US | $6.0M | 27 | 12.3% |
| 3 | ALEMBIC PHARMACEUTICALS LIMITED FEBUXOSTAT TABLETS 40MG 30 S AP USFEBUXOSTAT TABLETS 80MG 30'S AP USFEBUXOSTAT TABLETS 40MG 30'S AP US | $5.4M | 1 | 11.0% |
| 4 | LUPIN LIMITED URINORM TAB 40MG FEBUXOSTAT TABLETS 40URINORM TAB 40MG (FEBUXOSTAT TABLETS 40FURIC 40 10X10T FEBUXOSTAT TABLETS 40MG | $5.4M | 2 | 10.9% |
| 5 | MACLEODS PHARMACEUTICALS LTD FEBUXOSTAT TABLETS 40MG 30 S AP USMAR FEBUXOSTAT TABLETS 80MG 100T CAFEBUXOSTAT TABLETS 80MG 30'S AP US | $2.1M | 12 | 4.4% |
| 6 | EMCURE PHARMACEUTICALS LIMITED MAR FEBUXOSTAT TABLETS 80MG 100T CAFEBUXOSTAT TABLETS 80 MGMAR-FEBUXOSTAT TABLETS 80MG 100T CA,BATC | $2.0M | 7 | 4.1% |
| 7 | WATSON PHARMA PRIVATE LIMITED MAR FEBUXOSTAT TABLETS 80MG 100T CAFEBUXOSTAT FILM COATED TABLETS 80 MG 5 KFEBUXOSTAT FILM COATED TABLETS 80 MG 5 KG ( | $1.4M | 2 | 2.9% |
| 8 | INDOCO REMEDIES LIMITED FEBUXOSTAT TABLETS 40MG 30 S AP USFEBUXOSTAT TABLETS 80MG 30'S AP USFEBUXOSTAT TABLETS 40MG 30'S AP US | $976.4K | 3 | 2.0% |
| 9 | GLOBELA PHARMA PRIVATE LIMITED URINORM TAB 40MG FEBUXOSTAT TABLETS 40URINORM TAB 40MG (FEBUXOSTAT TABLETS 40FURIC 40 10X10T FEBUXOSTAT TABLETS 40MG | $565.3K | 1 | 1.2% |
| 10 | AET LABORATORIES PRIVATE LIMITED FEBUXOSTAT 80MG FILM COATED TABLETSFEBUXOSTAT 80MG FILM COATED TABLETSNOSFEBUXOSTAT 120MG FILM COATED TABLETS | $536.1K | 1 | 1.1% |
| 11 | STALLION LABORATORIES PVT LTD URINORM TAB 40MG FEBUXOSTAT TABLETS 40URINORM TAB 40MG (FEBUXOSTAT TABLETS 40FURIC 40 10X10T FEBUXOSTAT TABLETS 40MG | $478.4K | 2 | 1.0% |
| 12 | SUN PHARMACEUTICAL INDUSTRIES LIMITED URINORM TAB 40MG FEBUXOSTAT TABLETS 40URINORM TAB 40MG (FEBUXOSTAT TABLETS 40FEBUXOSTAT TABLETS 40MG 30 S AP US | $449.1K | 1 | 0.9% |
| 13 | MYLAN LABORATORIES LIMITED FEBUXOSTAT TAB 120MG 28BL FR MYMSN PHARMA- STATURIC 40 (FEBUXOSTAT 40MGSTATURIC 80 3X10 | $414.0K | 5 | 0.8% |
| 14 | ZYDUS LIFESCIENCES LIMITED FEBUXOSTAT TABLETS 40MG 30 S AP USFEBUXOSTAT TABLETS 80MG 30'S AP USFEBUXOSTAT TABLETS 40MG 30'S AP US | $398.4K | 5 | 0.8% |
| 15 | MICRO LABS LIMITED URINORM TAB 40MG FEBUXOSTAT TABLETS 40URINORM TAB 40MG (FEBUXOSTAT TABLETS 40FURIC 40 10X10T FEBUXOSTAT TABLETS 40MG | $392.0K | 10 | 0.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Febuxostat exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Ajanta Pharma Limited | Approved | Yes (January 27, 200 | Unknown | 27 | FDA-approved with 27 ANDAs; WHO-GMP certified since January 27, 2006. |
| Alembic Pharmaceuticals Limited | Approved | Unknown | Unknown | 223 | FDA-approved with 223 ANDAs; recent approvals include Rivaroxaban tablets (May 2 |
| Lupin Limited | Approved | Unknown | Unknown | Unknown | FDA-approved; listed under India's PLI Scheme for Pharmaceuticals as of May 3, 2 |
| MSN Laboratories Private Limited | Approved | Unknown | Unknown | Unknown | FDA-approved; listed under India's PLI Scheme for Pharmaceuticals as of May 3, 2 |
| Emcure Pharmaceuticals Limited | Approved | Unknown | Unknown | Unknown | FDA-approved; received FDA warning letter on August 2, 2019, for CGMP adulterati |
| Indoco Remedies Limited | Approved | Unknown | Unknown | Unknown | FDA-approved; received FDA warning letter on July 9, 2019, for CGMP adulteration |
| Macleods Pharmaceuticals Limited | Approved | Unknown | Unknown | Unknown | FDA-approved; listed under India's PLI Scheme for Pharmaceuticals as of May 3, 2 |
| Sun Pharmaceutical Industries Limited | Approved | Unknown | Unknown | Unknown | FDA-approved; listed under India's PLI Scheme for Pharmaceuticals as of May 3, 2 |
| Mylan Laboratories Limited | Approved | Unknown | Unknown | Unknown | FDA-approved; listed under India's PLI Scheme for Pharmaceuticals as of May 3, 2 |
TransData Nexus reviewed the regulatory standing of 9 leading Febuxostat exporters from India. 9 hold US FDA facility approvals, 1 maintain WHO-GMP certification, and 0 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Febuxostat sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for Active Pharmaceutical Ingredients (APIs) production. The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. This concentration of API manufacturers makes Hyderabad a critical source for the raw materials required in Febuxostat production.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its expertise in pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses companies such as Zydus Cadila and Torrent Pharmaceuticals. This region's focus on finished dosage forms positions it as a key player in the formulation and export of Febuxostat tablets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a major export gateway for pharmaceuticals, leveraging its proximity to major ports and well-established infrastructure. Companies like Lupin Limited, headquartered in Mumbai, have received approvals from regulatory bodies such as the U.S. FDA for Febuxostat tablets, underscoring the region's significance in the global supply chain.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub, housing over 500 pharmaceutical units. The region's appeal is enhanced by tax incentives and a favorable regulatory environment, attracting numerous manufacturers involved in the production of various pharmaceuticals, including Febuxostat.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with manufacturers across multiple clusters to mitigate risks associated with regional disruptions.
- Assess Regulatory Compliance: Prioritize suppliers with approvals from regulatory bodies such as the U.S. FDA and WHO to ensure product quality and compliance.
- Evaluate Logistics Infrastructure: Consider the logistical advantages of suppliers in export-centric regions like Mumbai-Thane-Raigad for efficient distribution.
- Monitor Tax Incentives: Stay informed about tax benefits in regions like Baddi-Nalagarh to optimize cost structures in sourcing decisions.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Febuxostat exporters from India
Lupin Limited — Lupin acquires French pharmaceutical company Medisol
In May 2023, Lupin Limited announced the acquisition of Medisol, a French pharmaceutical company, to enhance its presence in the European market. - IMPACT: This acquisition is expected to strengthen Lupin's distribution network in Europe, potentially increasing Febuxostat exports to the region.
Impact: This acquisition is expected to strengthen Lupin's distribution network in Europe, potentially increasing Febuxostat exports to the region.
Alembic Pharmaceuticals Limited — Alembic Pharmaceuticals acquires 100% stake in Aleor Dermaceuticals
In March 2022, Alembic Pharmaceuticals completed the acquisition of Aleor Dermaceuticals, aiming to expand its dermatology product portfolio. - IMPACT: While this acquisition focuses on dermatology, it may allow Alembic to reallocate resources to enhance Febuxostat production and exports.
Impact: While this acquisition focuses on dermatology, it may allow Alembic to reallocate resources to enhance Febuxostat production and exports.
Amneal Pharmaceuticals — Amneal acquires India's Punishka Healthcare
In November 2021, Amneal Pharmaceuticals acquired Punishka Healthcare, an Indian injectable manufacturer, to expand its manufacturing capabilities. - IMPACT: This acquisition may lead to increased competition in the Febuxostat market, potentially affecting export dynamics for existing exporters.
Impact: This acquisition may lead to increased competition in the Febuxostat market, potentially affecting export dynamics for existing exporters.
Common Questions — Febuxostat Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which febuxostat supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, AJANTA PHARMA LIMITED leads with 89 recorded shipments worth $16.8M. MSN LABORATORIES PRIVATE LIMITED (342 shipments) and ALEMBIC PHARMACEUTICALS LIMITED (56 shipments) are also established high-volume exporters.
Q How many febuxostat manufacturers are there in India?
India has 182 active febuxostat exporters with a combined export market of $48.9M across 3,494 shipments to 91 countries. The top 5 suppliers hold 73.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for febuxostat from India?
Average FOB unit price: $4.61 per unit, ranging from $0.00 to $1793.49. Average shipment value: $14.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 182 verified Indian exporters of Febuxostat ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,494 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 91 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,494 Verified Shipments
182 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists